Coya Therapeutics (NASDAQ: COYA) files 8-K on Sept. 30 2025 quarter results

Rhea-AI Filing Summary

Coya Therapeutics, Inc. filed a current report to note that it issued a press release on November 12, 2025 disclosing information about its results of operations for the fiscal quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 under Item 2.02, and the same information is also referenced under Item 7.01 for Regulation FD disclosure. The company states that this information is being furnished, not filed, so it is not subject to liability under Section 18 of the Exchange Act unless later specifically incorporated by reference into another filing.

0001835022false00018350222025-11-122025-11-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

Coya Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41583	85-4017781
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
5850 San Felipe St., Suite 500
Houston, Texas				77057
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 800 587-8170

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		COYA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 12, 2025, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal quarter ended September 30, 2025. A copy of the press release is furnished under Item 2.02 of this Current Report on Form 8-K as Exhibit 99.1.

The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 7.01. Regulation FD Disclosure.

See “Item 2.02 Results of Operations and Financial Condition” above.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated November 12, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			COYA THERAPEUTICS, INC.
Date:	November 12, 2025	By:	/s/ Arun Swaminathan Ph.D.
			Arun Swaminathan Ph.D. Chief Executive Officer (Principal Executive Officer)

FAQ

What did Coya Therapeutics (COYA) disclose in this 8-K filing?

Coya Therapeutics, Inc. disclosed that it issued a press release on November 12, 2025 providing information about its results of operations for the fiscal quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.

Which period do the Coya Therapeutics (COYA) results in the press release cover?

The press release furnished with this report discusses Coya Therapeutics, Inc.'s results of operations for the fiscal quarter ended September 30, 2025.

How is the Coya Therapeutics (COYA) press release treated for SEC purposes?

The information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is therefore not subject to liability under Section 18 of the Exchange Act unless it is expressly incorporated by reference into another filing.

What is Exhibit 99.1 in the Coya Therapeutics (COYA) 8-K?

Exhibit 99.1 is the press release dated November 12, 2025 in which Coya Therapeutics, Inc. discloses certain information about its results of operations for the fiscal quarter ended September 30, 2025.

Which items of Form 8-K does Coya Therapeutics (COYA) use in this report?

The report uses Item 2.02 for Results of Operations and Financial Condition and Item 7.01 for Regulation FD Disclosure, with Item 7.01 referencing the same information described in Item 2.02.

Who signed the Coya Therapeutics (COYA) 8-K report?

The report was signed on behalf of Coya Therapeutics, Inc. by Arun Swaminathan, Ph.D., who is the Chief Executive Officer and principal executive officer.